natgillin/translations-raw huggingface dataset:
Patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.
Bolesnici s nasljednim problemima intolerancije galaktoze, nedostatka Lapp laktaze ili malapsorpcije glukoze-galaktoze ne bi smjeli uzimati ovaj lijek.
Please inform your doctor about all other medicines you are taking especially: antidepressants, alpha-methyldopa (used to treat increased blood pressure), apomorphine (used for Parkinson's disease), dobutamine (used for the chronic heart disease), adrenaline and isoprenaline (both used for heart attacks) anticoagulants of the warfarin type (that prevent blood clotting).
Obavijestite svog liječnika o svim lijekovima koje uzimate, osobito ako su to: - antidepresivi, - alfa-metildopa (koristi se za liječenje povišenog krvnog tlaka), - apomorfin (koristi se za Parkinsonovu bolest), - dobutamin (koristi se za kroničnu bolest srca), - adrenalin i izoprenalin (oboje se koriste za srčane udare), - antikoagulansi varfarinskog tipa (koji sprječavaju zgrušavanje krvi).
The only adverse reaction commonly leading to discontinuation of Tasmar in clinical trials was diarrhoea (see section 4.4).
Jedina nuspojava koja je obično vodila do prekida liječenja Tasmarom u kliničkim ispitivanjima bio je proljev (vidjeti dio 4.4).
No information on the tolerability of tolcapone in these populations is available (see section 5.2).
Nisu dostupni podaci o podnošljivosti tolkapona u ovim populacijama (vidjeti dio 5.2).
MAO inhibitors: Tasmar should not be given in conjunction with non-selective monoamine oxidase (MAO) inhibitors (e.g. phenelzine and tranylcypromine).
MAO inhibitori: Tasmar se ne smije davati zajedno s neselektivnim inhibirotima monoaminooksidaze (MAO) (npr. fenelzin i tranilcipromin).
How to take Tasmar
Kako uzimati Tasmar
The peak plasma concentrations of tolcapone at this dose were on average 30 µg/ml (compared to 3 and 6 µg/ml with 100 mg tid and 200 mg tid of tolcapone respectively).
Vršne koncentracije tolkapona u plazmi pri ovoj dozi bile su prosječno 30 µg/ml (u usporedbi s 3 i 6 µg/ml sa 100 mg tolkapona tri puta dnevno, odnosno 200 mg tolkapona tri puta dnevno).
In addition, rhabdomyolysis, secondary to NMS or severe dyskinesia, has been observed.
Uz to, opažene su rabdomioliza sekundarna NMS-u ili teška diskinezija.
Treatment with non-selective mono amino oxidase (MAO) inhibitors
• Liječenje neselektivnim inhibitorima monoaminoksidaze (MAO)
Tasmar can be combined with all pharmaceutical formulations of levodopa/benserazide and levodopa/carbidopa (see also section 4.5).
Tasmar se može kombinirati sa svim farmaceutskim oblicima levodope/benzerazida i levodope/karbidope (vidjeti također dio 4.5).
Review of treatment is recommended if such symptoms develop.
Ako se razviju takvi simptomi, preporučuje se ponovno razmatranje liječenja.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose malabsorption should not take this medicine.
Bolesnici s rijetkim nasljednim problemima intolerancije galaktoze, nedostatka Lapp laktaze ili malapsorpcije glukoze ne bi smjeli uzimati ovaj lijek.
Evidence of liver disease or increased liver enzymes Severe dyskinesia
• Dokazi o bolesti jetre ili povišeni jetreni enzimi
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments such as Tasmar in association with levodopa.
Bolesnici i njegovatelji trebaju biti svjesni da bihevioralni simptomi poremećaja kontrole impulsa uključujući patološko kockanje, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje mogu se javiti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim liječenjima kao što je Tasmar u kombinaciji s levodopom.
This means when it is taken together with levodopa (as levodopa/benserazide or levodopa/carbidopa) you should have an improvement in the symptoms of your Parkinson's disease.
To znači da biste tijekom uzimanja ovog lijeka zajedno s levodopom (kao levodopa/benzerazid ili levodopa/karbidopa) trebali iskusiti poboljašanje simptoma Parkinsonove bolesti.
Hypersensitivity to tolcapone or any of its other ingredients listed in section 6.1.
• Preosjetljivost na tolkapon ili neku od pomoćnih tavri navedenih u dijelu 6.1.
Date of first authorisation: 27 August 1997 Renewal of the authorisation: 31 August 2004 Date of latest renewal: 21 July 2014
Datum posljednje obnove: 21. srpanj 2014.
Treatment should be immediately discontinued if ALT and/or AST exceed the upper limit of normal or if symptoms or signs suggesting the onset of hepatic failure (persistent nausea, fatigue, lethargy, anorexia, jaundice, dark urine, pruritus, right upper quadrant tenderness) develop.
Liječenje treba odmah prekinuti ako ALT i/ili AST premaše gornju granicu normale ili se razviju simptomi ili znakovi koji upućuju na nastup zatajenja jetre (dugotrajna mučnina, umor, letargija, anoreksija, žutica, tamni urin, pruritus, osjetljivost gornjeg desnog kvadranta).
1 film-coated tablet Tasmar
1 filmom obložena tableta Tasmar
The plasma concentrations of benserazide observed after co-administration of tolcapone and benserazide-25 mg/levodopa were still within the range of values observed with levodopa/benserazide alone.
Koncentracije benzerazida u plazmi opažene nakon istodobne primjene tolkapona i benzerazida25 mg/levodope bile su još uvijek unutar raspona vrijednosti opaženih samo s levodopom/benzerazidom.
While receiving treatment: During treatment, blood tests will be done in the following time intervals: every 2 weeks during the first 12 months of therapy, every 4 weeks during the following 6 months of therapy, every 8 weeks during further treatment.
Tijekom liječenja će krvni testovi biti učinjeni u sljedećim vremenskim razmacima: - svaka 2 tjedna tijekom prvih 12 mjeseci terapije, - svaka 4 tjedna tijekom sljedećih 6 mjeseci terapije, - svakih 8 tjedana tijekom daljnjeg liječenja.
Dyskinesia, nausea and other levodopa-associated adverse reactions: Patients may experience an increase in levodopa-associated adverse reactions.
Diskinezija, mučnina i druge nuspojave povezane s levodopom: bolesnici mogu iskusiti povećanje nuspojava povezanih s levodopom.
Patients with renal impairment (see section 5.2)
Bolesnici s oštećenjem bubrega (vidjeti dio 5.2)
“TASMAR” and “100” are engraved on one side.
“TASMAR” i “100” su ugravirani na jednoj strani.
30 film-coated tablets 60 film-coated tablets 100 film-coated tablets 200 film-coated tablets
30 filmom obloženih tableta 60 filmom obloženih tableta 100 filmom obloženih tableta 200 filmom obloženih tableta
The most commonly observed adverse reactions associated with the use of Tasmar, occurring more frequently than in placebo-treated patients are listed in the table below.
Najčešće opažene nuspojave povezane s primjenom Tasmara koje su se javljale češće nego u bolesnika koji su primali placebo navedene su u tablici ispod.
Renal impairment: The pharmacokinetics of tolcapone have not been investigated in patients with renal impairment.
Oštećenje bubrega: farmakokinetika tolkapona nije istražena u bolesnika s oštećenjem bubrega.
The prescriber should be observant of adverse reactions caused by putative increased plasma levels of these drugs when combined with Tasmar.
Liječnikkoji propisuje lijek treba pozorno pratiti moguće nuspojave prouzročenih putativnim povećanjem plazmatskih razina ovih lijekova kada se uzimaju istodobno s Tasmarom.
Increase of alanine aminotransferase (ALT)
Pretrage često povećanje alanin aminotransferaze (ALT)
Orange yellow to brown yellow, hexagonal, biconvex, film-coated tablet.
Narančasto žuta do smeđe žuta, heksagonalna, bikonveksna, filmom obložena tableta.
No information on the tolerability of tolcapone in these populations is available (see section 5.2)
Nisu dostupni podaci o podnošljivosti tolkapona u ovim populacijama (vidjeti dio 5.2)
Film-coat: Hydroxypropylmethylcellulose, Talc, Yellow iron oxide, Ethylcellulose, Titanium dioxide, Triacetin, Sodium lauril sulfate.
Film ovojnica: hidroksipropilmetilceluloza, talk, žuti željezov oksid, etilceluloza, titanijev dioksid, triacetin, natrijev laurilsulfat.
o
I
During treatment: Liver function should be monitored every 2 weeks for the first year of therapy, every 4 weeks for the next 6 months and every 8 weeks thereafter.
Tijekom liječenja: funkciju jetre treba nadzirati svaka 2 tjedna tijekom prve godine terapije, svaka 4 tjedna tijekom sljedećih 6 mjeseci te svakih 8 tjedana nakon toga.
“TASMAR” and “200” are engraved on one side.
“TASMAR” i “200” su ugravirani na jednoj strani.
Increases to more than three times the upper limit of normal (ULN) in alanine aminotransferase (ALT)occurred in 1 % of patients receiving Tasmar 100 mg three times daily, and 3 % of patients at 200 mg three times daily.
Povećanja na više od tri puta od gornje granice normale (GGN) u alanin aminotransferazi (ALT) javila su se u 1 % bolesnika koji su primali Tasmar 100 mg tri puta dnevno i 3 % bolesnika koji su primali 200 mg tri puta dnevno.
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, 4.2)
Lijek se izdaje na ograničeni recept (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2)
The consequent increase in dopaminergic stimulation can lead to the dopaminergic adverse reactions observed after treatment with COMT inhibitors.
Posljedično povećanje dopaminergičke stimulacije može voditi do dopaminergičkih nuspojava opaženih nakon liječenja COMT inhibitorima.
severe symptoms of muscle stiffening, fever or mental confusion (Neuroleptic Malignant Syndrome) when antiparkinsonian treatments are abruptly reduced or withdrawn - Impulse control disorders (inability to resist the impulse of an action that could be harmful).
Rijetko: - teški simptomi ukočenosti mišića, vrućica ili mentalna smetenost (neuroleptički maligni sindrom) kada se liječenje lijekovima za Parkinsonovu bolest naglo smanji ili ukine - poremećaj kontrole impulsa (nemogućnost odupiranja impulsu za neki postupak koji može biti štetan)
Tolcapone's effect on levodopa pharmacokinetics is similar with all pharmaceutical formulations of levodopa/benserazide and levodopa/carbidopa; it is independent of levodopa dose, levodopa/AADC-I (benserazide or carbidopa) ratio and the use of sustained-release formulations.
Učinak tolkapona na farmakokinetiku levodope sličan je kod svih farmaceutskih oblika levodope/benzerazida i levodope/karbidope; neovisan je o dozi levodope, omjeru levodope/AADC-I (benzerazid ili karbidopa) te primjeni oblika s produljenim oslobađanjem.
Neuroleptic Malignant Syndrome Symptom Complex
Grupa simptoma neuroleptičkog malignog sindroma
Special populations: Patients with severe renal impairment (creatinine clearance <30 ml/min) should be treated with caution.
Posebne populacije: bolesnike s teškim oštećenjem jetre (klirens kreatinina <30 ml/min) treba liječiti s oprezom.
The data of more than 400 patients have confirmed that over a wide range of creatinine clearance values (30-130 mL/min) the pharmacokinetics of tolcapone are unaffected by renal function.
Podaci o više od 400 bolesnika potvrdili su da bubrežna funkcija ne utječe na farmakokinetiku tolkapona kroz široki raspon vrijednosti klirensa kreatinina (30130 ml/min).
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed (non-prescription medicines and herbals).
Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli bilo koje druge lijekove, uključujući i one koji nisu propisani (bezreceptne i biljne lijekove).
Diarrhoea: In clinical trials, diarrhoea developed in 16 % and 18 % of patients receiving Tasmar 100 mg tid and 200 mg tid respectively, compared to 8 % of patients receiving placebo.
Proljev: u kliničkim ispitivanjima, proljev je razvilo 16 % i 18 % bolesnika koji su uzimali Tasmar 100 mg tri puta dnevno, odnosno 200 mg tri puta dnevno, u usporedbi s 8 % bolesnika koji su primali placebo.
If treatment is discontinued: Patients who show evidence of acute liver injury while on Tasmar and are withdrawn from the medicinal product may be at increased risk for liver injury if Tasmar is reintroduced.
Ako se prekida liječenje: bolesnici koji pokazuju znakove akutnog oštećenja jetre dok su na Tasmaru i koji prestanu uzimati taj lijek mogu imati povećani rizik od oštećenja jetre kod ponovnog uvođenja Tasmara.
This may include: o
To može uključivati:
The treatment will be stopped, if these blood tests become abnormal.
Ako ovi krvni nalazi budu abnormalni, liječenje će biti prekinuto.
Tell your doctor or a pharmacist as soon as possible: if you do not feel well while you are taking Tasmar if you experience symptoms such as nausea, vomiting, abdominal pain, loss of appetite, weakness, fever, darkening of urine or jaundice since uncommonly disturbances in the way the liver works, sometimes severe hepatitis was observed, if you notice a darkening of your urine since this could be a sign of a muscular or liver injury.
Obavijestite svog liječnika ili ljekarnika što je prije moguće: - ako se ne osjećate dobro dok uzimate Tasmar - ako imate simptome kao što su mučnina, povraćanje, bol u trbuhu, gubitak apetita, slabost, vrućica, tamnija mokraća ili žutica jer su manje često opaženi poremećaji u načinu rada jetre, a ponekad i teški hepatitis, - ako primijetite da Vam je mokraća tamnija jer to može bit znak mišićnog ili jetrenog oštećenja.
Marketing Authorisation Holder: Meda AB
Nositelj odobrenja za stavljanje gotovoga lijeka u promet Meda AB
The consequent increase in dopaminergic stimulation can lead to the dopaminergic side effects observed after treatment with COMT inhibitors.
Posljedično povećanje dopaminergičke stimulacije može dovesti do dopaminergičkih nuspojava opaženih nakon liječenja COMT inhibitorima.
A natural protein (enzyme) in your body, the (COMT) Catechol-O-methyltransferase in your body breaks down levodopa.
Prirodni protein (enzim) u Vašem tijelu, katehol-O-metiltransferaza (engl. catechol-Omethyltransferase, (COMT) razgrađuje levodopu u Vašem tijelu.
Because of the risk of rare but potentially fatal acute liver injury, Tasmar is only indicated for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations, who failed to respond to or are intolerant of other COMT inhibitors.
Oštećenje jetre: zbog rizika od rijetkog, ali potencijalno smrtonosnog, akutnog oštećenja jetre, Tasmar je indiciran samo za primjenu u bolesnika s idiopatskom Parkinsonovom bolešću koja odgovara na levodopu i motoričkim fluktuacijama, a koji nisu odgovarali ili su intolerantni na druge COMT inhibitore.
Since clinical information is limited regarding the combination of warfarin and tolcapone, coagulation parameters should be monitored when these drugs are co-administered.
Budući da su klinički podaci koji se odnose na kombinaciju varfarina i tolkapona ograničeni, parametri koagulacije se moraju nadzirati kada se ovi lijekovi primjenjuju istodobno.
If benefits are not seen within 3 weeks of the initiation of the treatment, Tasmar should be discontinued.
Ako se unutar 3 tjedna od početka liječenja ne vide koristi, liječenje Tasmarom treba prekinuti.
Patients with severe renal impairment (creatinine clearance <30 ml/min) should be treated with caution.
Bolesnike s teškim oštećenjem bubrega (klirens kreatinina <30 ml/min) treba liječiti s oprezom.
If the dose is increased to 200 mg tid, liver enzyme monitoring should take place before increasing the dose and then be reinitiated following the same sequence of frequencies as above (see sections 4.4 and 4.8).
Ako se doza poveća na 200 mg tri puta dnevno, prije povećanja doze treba nadzirati jetrene enzime, a zatim ponovno nadzirati prema jednakom slijedu učestalosti koji je naveden gore (vidjeti dijelove 4.4 i 4.8).
The most common of these are increased dyskinesia, nausea, vomiting, abdominal pain, syncope, orthostatic complains, constipation, sleep disorders, somnolence, hallucination.
Najčešće od njih su pojačana diskinezija, mučnina, povraćanje, bol u abdomenu, sinkopa, ortostatske smetnje, konstipacija, poremećaji spavanja, somnolencija, halucinacije.
Outer Carton and bottle label, 30, 60, 100, 200 film-coated tablets
Kartonska kutija i naljepnica na bočici, 30, 60, 100, 200 filmom obloženih tableta
A natural protein (enzyme) in your body, the (COMT) Catechol-O-methyltransferase breaks down the levodopa.
Prirodni protein (enzim) u Vašem tijelu, katehol-O-metiltransferaza (engl. catechol-Omethyltransferase, (COMT) razgrađuje levodopu.
Liver function should be checked before starting treatment with Tasmar and then monitored every 2 weeks for the first year of therapy, every 4 weeks for the next 6 months and every 8 weeks thereafter.
Prije liječenja Tasmarom treba provjeriti jetrenu funkciju, a zatim je nadzirati svaka 2 tjedna tijekom prve godine terapije, svaka 4 tjedna tijekom sljedećih 6 mjeseci i svakih 8 tjedana nakon toga.
Plasma levels of 3OMD were markedly and dose-dependently decreased by tolcapone when given with levodopa/AADC-I (aromatic amino acid decarboxylase - inhibitor) (benserazide or carbidopa).
Tolkapon je značajno i ovisno o dozi smanjio plazmatske razine 3-OMD-a kada se davao s levodopom/AADC-I (inhibitor dekarboksilaze aromatske aminokiseline) (benzerazid ili karbidopa).
Česká republika MEDA Pharma s.r.o.
Slovenská republika MEDA Pharma spol. s. r.o.
While receiving treatment:
Tijekom liječenja:
Outer Carton and blister packs, 30 and 60 film-coated tablets
Vanjska kutija i blister pakiranja, 30 i 60 filmom obloženih tableta
Diarrhoea led to withdrawal of 5% and 6% of patients receiving Tasmar 100 mg tid and 200 mg tid respectively, compared to 1 % of patients receiving placebo.
Proljev je doveo do odustajanja kod 5 % i 6 % bolesnika koji su primali Tasmar 100 mg tri puta dnevno, odnosno 200 mg tri puta dnevno, u usporedbi s 1 % bolesnika koji su primali placebo.
C/Plom, 2-4, 5ª planta 08038 - Barcelona Tel: +34 900 102 712
Mylan Pharmaceuticals S.L. C/Plom, 2-4, 5ª planta 08038 - Barcelona Tel: +34 900 102 712
Mylan Healthcare B.V Krijgsman 20
Mylan Healthcare B.V
To improve efficacy your doctor should only increase the dose to 3 times daily 2 tablets (200 mg three times a day) if the increase in how your Parkinson´s disease symptoms are controlled outweighs the expected increase in side effects.The side effects at the higher dose can often be severe and affect your liver.
Kako bi poboljšao učinkovitost Vaš liječnik smije dozu povećati samo na 3 puta dnevno po 2 tablete (200 mg tri puta dnevno), ako poboljšanje u kontroliranju simptoma Parkinsonove bolesti nadjačava očekivano pojačanje nuspojava.
Rare (≥1/10,000 to < 1/1,000)
Rijetko (≥1/10 000 i < 1/1000)
If the dose is increased to 200 mg tid, liver enzyme monitoring should take place before increasing the dose and then be re-initiated following the sequence of frequencies as above.
Ako se doza poveća na 200 mg tri puta dnevno, prije povećanja doze treba nadzirati jetrene enzime, a zatim ponovno nadzirati prema jednakom slijedu učestalosti koji je naveden gore.
30 film-coated tablets 60 film-coated tablets
30 filmom obloženih tableta 60 filmom obloženih tableta
It is available in blisters in pack sizes of 30 and 60 tablets and in glass bottles in pack sizes of 100 tablets.
Dostupne su u blisterima u veličinama pakiranja od 30 i 60 tableta te u staklenim bočicama u veličinama pakiranja od 100 tableta.
In the therapeutic range, tolcapone pharmacokinetics are linear and independent of levodopa/AADC-I (benserazide or carbidopa) coadministration.
U terapijskom rasponu, farmakokinetika tolkapona je linearna i neovisna o istodobnoj primjeni levodope/AADC-I (benzerazid ili karbidopa).
Tasmar is available in PVC/PE/PVDC blisters (pack sizes of 30 and 60 film-coated tablets) and in amber glass bottles without desiccant (pack sizes of 100 film-coated tablets).
Tasmar je dostupan u PVC/PE/PVDC blisterima (veličine pakiranja od 30 i 60 filmom obloženih tableta) i u staklenim bočicama boje jantara bez sredstva za sušenje (veličine pakiranja od 100 filmom obloženih tableta).
severe symptoms of muscle stiffening, fever or mental confusion (Neuroleptic Malignant Syndrome) when antiparkinsonian treatments are abruptly reduced or withdrawn.
Rijetko: - teški simptomi ukočenosti mišića, vrućica ili mentalna smetenost (neuroleptički maligni sindrom) kada se liječenje lijekovima za Parkinsonovu bolest naglo smanji ili ukine
It is available in blisters in pack sizes of 30 and 60 tablets and in glass bottles in pack sizes of 30, 60 ,100 and 200 filmcoated tablets.
Dostupne su u blisterima u veličinama pakiranja od 30 i 60 tableta te u staklenim bočicama u veličinama pakiranja od 30, 60, 100 i 200 filmom obloženih tableta.
may affect more than 1 in 10 people
mogu se javiti u više od 1 na 10 osoba
Pale to light yellow, hexagonal, biconvex, film-coated tablet.
Blijeda do svijetložuta, heksagonalna, bikonveksna, filmom obložena tableta.
Warfarin: Since clinical information is limited regarding the combination of warfarin and tolcapone, coagulation parameters should be monitored when these drugs are co-administered.
Varfarin: budući da je kliničko iskustvo s kombinacijom varfarina i tolkapona ograničeno, trebalo bi nadzirati parametre koagulacije kada se ovi lijekovi primjenjuju istodobno.
Tasmar is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-o-methyltransferase (COMT) inhibitors (see section 5.1).
Tasmar je indiciran u kombinaciji s levodopom/benzerazidom ili levodopom/karbidopom za primjenu u bolesnika s idiopatskom Parkinsonovom bolešću koja odgovara na levodopu i motoričkim fluktuacijama, a koji nisu odgovarali ili su intolerantni na druge inhibitore katehol-O-metiltransferaze (COMT, engl. catechol-O-methyltransferase) (vidjeti dio 5.1).
EU/1/97/044/006 100 tablets
EU/1/97/044/006 100 tableta
Rare cases of severe hepatocellular injury resulting in death have been reported during marketed use (see section 4.4).
Tijekom tržišne primjene prijavljeni su rijetki slučajevi hepatocelularnog oštećenja sa smrtnim ishodom (vidjeti dio 4.4).
How to store Tasmar
Kako čuvati Tasmar
Hepatocellular injury, in rare cases with fatal outcome* (see section 4.4)
Poremećaji jetre i žuči manje često hepatocelularno oštećenje, u rijetkim slučajevima s fatalnim ishodom (vidjeti dio 4.4)
Skin and subcutaneous tissue disorders
Poremećaji kože i potkožnog tkiva često pojačano znojenje
EU/1/97/044/007 30 tablets EU/1/97/044/008 60 tablets EU/1/97/044/003 100 tablets EU/1/97/044/0010 200 tablets
EU/1/97/044/007 30 tableta EU/1/97/044/008 60 tableta EU/1/97/044/003 100 tableta EU/1/97/044/0010 200 tableta
Tasmar is available in PVC/PE/PVDC blisters (pack sizes of 30 and 60 film-coated tablets) and in amber glass bottles without desiccant (pack sizes of 30, 60,100 and 200 film-coated tablets).
Tasmar je dostupan u PVC/PE/PVDC blisterima (veličine pakiranja od 30 i 60 filmom obloženih tableta) i u staklenim bočicama boje jantara bez sredstva za sušenje (veličine pakiranja od 30, 60, 100 i 200 filmom obloženih tableta).
The following suggestions are based on pharmacological considerations and have not been evaluated in clinical trials.
Prilagodbe levodope pri ukidanju Tasmara: sljedeće sugestije temelje se na farmakološkim razmatranjima te nisu vrednovane u kliničkim ispitivanjima.
Common (≥1/100 to < 1/10)
Često (≥1/100 i < 1/10)